We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Zsuzsanna
Iyizoba-Ebozue
Zsuzsanna.iyizoba@nhs.net
Louise
Murray
Louise.Murray8@nhs.net
Other and unspecified effects of external causesMalignant neoplasms of lip, oral cavity and pharynx
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Oropharyngeal cancer (OPC) a type of head and neck cancer. Patients treated with radiotherapy for OPC receive a low dose of radiotherapy to the base of the brain. This could lead to side effects including fatigue and neurocognitive problems ( e.g., problems with memory, language, processing speed and attention). Traditional testing for neurocognitive problems involves a trained individual carrying out assessments in a controlled, face-to-face setting which may last between one to several hours.This is the standard of care. The Amsterdam Cognition Scan (ACS) is a new online neurocognitive test platform where participants complete a series of game like tasks, such as memorising a list of words and completing some simple tasks. The ACS can be completed on a computer from home.
The phase III TORPEdO trial (TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer) compares proton beam therapy, a new type of radiotherapy that delivers reduced doses to normal tissue (including the brain in OPC patients) with traditional photon radiotherapy.
We want to conduct a study within the TORPEdO trial, to find out if the ACS is a useful tool for remote neurocognitive assessment in a trial setting.
We will invite TORPEdO trial participants who live outside of Leeds/ Manchester to complete the ACS.
We will invite TORPEdO trial participants who live in the Leeds/ Manchester region to be randomised between i) completing the ACS and, 6 months later completing face to face traditional neurocognitive testing and ii) completing traditional neurocognitive testing and, 6 months later completing the ACS.
We will ask all participants to complete a questionnaire about using the ACS and interview a proportion.
Based on the results, we will assess if the ACS is useful. We will also see how the neurocognitive outcomes relate to the dose received by the base of the brain during radiotherapy.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
- Upfront surgery or Salvage surgery - Unable to give consent - Existing neurological condition that may impact on neurocognitive assessment - Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (any such existing conditions will be discussed with the patient before registration) -
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Leeds and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 55933
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
